CD8A and neoplasm: One of the immunotherapies is based on the activation of CD8+ T cells through blocking immune checkpoints by antibodies targeting PD-1 and CTLA4 in CD8+ T cells [4], enhancing CD8+ T cells to recognize tumor cells by TCR-MHCI:neoantigens interaction and secrete granzymes and perforin to elicit tumor cell apoptosis and death [5].